Stanley Lipkowitz

22PUBLICATIONS
112CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Cancer cell biologyCancer genetics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (22)

|Jun 29, 2026
Small molecule activators of the mitochondrial protease ClpP induce senescence in triple-negative breast cancer cells and sensitize cells to the Bcl-2 inhibitor venetoclax.

|Jun 04, 2026
Loss of Flotillin-2 enhances trastuzumab emtansine internalization and cytotoxicity by relieving negative regulation of HER2 internalization in HER2-amplified cancers.

|Mar 17, 2026
Durvalumab and cediranib with and without olaparib in recurrent ovarian cancer: a phase II proof-of-concept study.

Junya Tabata, Tzu-Ting Huang, Elena Giudice

|Dec 08, 2025
A Phase II Pilot Study of Anti-PD-L1, Durvalumab, and a PARP Inhibitor, Olaparib in Patients With Metastatic Triple-Negative Breast Cancer With or Without Germline BRCA Mutation.

Takeo Fujii, Ashley Cimino-Mathews, Stanley Lipkowitz

|Dec 03, 2025
Small Molecule Activators of the Mitochondrial Protease ClpP Induce Senescence in Triple-Negative Breast Cancer Cells and Sensitize Cells to the Bcl-2 Inhibitor Venetoclax.

Sabrina C D Daglish, Owen G Canterbury, Paul R Graves

|Nov 25, 2025
EGFR amplification and PI3K pathway mutations identify a subset of breast cancers that synergistically respond to EGFR and PI3K inhibition.

David J Wisniewski, Donna Voeller, Yonit A Addissie

Pageof 4

Frequent Collaborators

6 joint publications

Yoshimi Greer

4 joint publications

Alexandra Zimmer

3 joint publications

Shraddha Rastogi

3 joint publications

Nahoko Sato